Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-10
2011-05-10
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07939529
ABSTRACT:
The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.
REFERENCES:
patent: 3761477 (1973-09-01), Schwartz et al.
patent: 3868380 (1975-02-01), Molteni et al.
patent: 4010279 (1977-03-01), Griss et al.
patent: 6538960 (2003-03-01), Sabi et al.
patent: 6624180 (2003-09-01), South et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 6969726 (2005-11-01), Lou et al.
patent: 7300931 (2007-11-01), Hangauer, Jr.
patent: 2004/0242572 (2004-12-01), Stenkamp et al.
patent: 2005/0043317 (2005-02-01), Zhou et al.
patent: 2005/0059713 (2005-03-01), Mjalli et al.
patent: 2006/0100245 (2006-05-01), Bakthavatchalam et al.
patent: 2006/0160800 (2006-07-01), Hangauer, Jr.
patent: 2007/0015752 (2007-01-01), Hangauer, Jr.
patent: 2007/0197783 (2007-08-01), Hangauer, Jr.
patent: 0 463 638 (1992-01-01), None
patent: WO-9219208 (1992-11-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/01127 (1999-01-01), None
patent: WO-0119788 (2001-03-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/059903 (2003-07-01), None
patent: WO 03/078404 (2003-09-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO-03093248 (2003-11-01), None
patent: WO 2004/011427 (2004-02-01), None
patent: WO-2004011456 (2004-02-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO-2004078747 (2004-09-01), None
patent: WO 2005/013914 (2005-02-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2006/071960 (2006-07-01), None
patent: WO 2007/026920 (2007-03-01), None
patent: WO-2007095383 (2007-08-01), None
patent: WO-2007136790 (2007-11-01), None
patent: WO-2008002676 (2008-01-01), None
patent: WO-2008082637 (2008-07-01), None
Cain et al., “Potential Antitumor Agents. IX. Bisquaternary Salts”,J. Med. Chem.,11(5):963-966 (1968).
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”,Biochemistry, 43:11658-11671 (2004).
Duong et al., “Inhibition of osteoclast function by adenovirus expressing Antisense protein-tyrosine kinase 2”,J. Biol. Chem., 276(10):7484-7492 (2001).
Frame, M.C., “Src in cancer:deregulation and consequences for cell behaviour”,Biochem. Biophys. Acta, 1602:114-130 (2002).
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”,Science, 286:531-537 (1999).
Guo et al., “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”,J. Neurosci., 22(14):6208-6217 (2002).
Hadjeri et al., “Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones”.J. Med. Chem., 47:4964-4970 (2004).
Huff, J.R., “HIV Protease: A Novel Chemotherapeutic Target for AIDS”,J. Med. Chem., 34(8):2305-2314 (1991).
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors”,Cancer Metastasis Rev., 17(1):91-106 (1998).
Liechti et al., “Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor”,Eur. J. Med. Chem., 39(1):11-26 (2004).
Million et al., “Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives”,J. Med. Chem., 38(23):4693-4703 (1995).
Miyazaki et al., “Src kinase activity is essential for osteoclast function”,J. Biol. Chem., 279(17):17660-17666 (2004).
Parang et al., “Recent advances in the discovery of Src kinase inhibitors”,Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).
Paul et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”,Nat. Med., 7(2):222-227 (2001).
Rouhi, A.M., “The right stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls”,Chem. Eng. News, pp. 32-35 (2003).
U.S. Pharmacopia #23, National Formulary #18, pp. 1843-1844 (1995).
Yu et al., “Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors”, Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).
Zhang et al., “Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs”,Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).
Bryn et al., “Hydrates and Solvates”, inSolid-State Chem. Drugs, 2nd Ed., SSCI, Inc., IN, Ch. 11, pp. 233-247 (1999).
Honma et al., “Antiallergic agents. 2. N-(1H-Tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides”,J. Med. Chem., 26:1499-1504 (1983).
Planas-Silva et al., “Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins”, Cancer Chemotherapy Pharmacol., 60(4):535-543 (2006).
Cody Jeremy A.
Coughlin Daniel
Gale Jonathan
Hangauer, Jr. David G.
Isbester Paul K.
Elrifi Ivor R.
Erlacher Heidi A.
Henley, III Raymond J
Kinex Pharmaceuticals, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Process for the preparation of compositions for modulating a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of compositions for modulating a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of compositions for modulating a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652103